Rigel Pharmaceuticals (RIGL) Research & Development (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Research & Development of $11.7 million for Q1 2026, up 38.41% year-over-year from $8.4 million in Q1 2025, and up 9.27% quarter-over-quarter from $10.7 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Research & Development (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Research & Development history runs 17 years deep, the most recent figure standing at $11.7 million for Q1 2026.
- In Q1 2026, Research & Development rose 38.41% year-over-year to $11.7 million; the TTM figure through Mar 2026 stood at $36.5 million (up 41.66% YoY), while the FY2025 annual figure was $33.3 million, up 42.41% from the prior year.
- Research & Development for Q1 2026 stood at $11.7 million, up from $10.7 million in the prior quarter.
- The five-year high for Research & Development was $15.5 million in Q1 2022, with the low at $2.5 million in Q4 2022.
- The 5-year median for Research & Development is $6.8 million (2025), against an average of $8.3 million.
- The sharpest annual moves came in 2022 and 2025: Research & Development sank 81.21% in 2022, then surged 89.72% in 2025.
- Rigel Pharmaceuticals' Research & Development stood at $2.5 million in 2022, then climbed by 27.44% to $3.2 million in 2023, then soared by 76.77% to $5.6 million in 2024, then soared by 89.72% to $10.7 million in 2025, then gained by 9.27% to $11.7 million in 2026.
- Business Quant data shows RIGL's Research & Development at $11.7 million in Q1 2026, $10.7 million in Q4 2025, and $7.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 13.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.96 Mn |
| Mar 31, 2026 | 11.68 Mn |
| Dec 31, 2025 | 10.69 Mn |
| Sep 30, 2025 | 7.35 Mn |
| Jun 30, 2025 | 6.82 Mn |
| Mar 31, 2025 | 8.44 Mn |
| Dec 31, 2024 | 5.63 Mn |
| Sep 30, 2024 | 6.18 Mn |
| Jun 30, 2024 | 5.54 Mn |
| Mar 31, 2024 | 6.03 Mn |
| Dec 31, 2023 | 3.19 Mn |
| Sep 30, 2023 | 6.48 Mn |
| Jun 30, 2023 | 4.77 Mn |
| Mar 31, 2023 | 10.09 Mn |
| Dec 31, 2022 | 2.50 Mn |
| Sep 30, 2022 | 14.67 Mn |
| Jun 30, 2022 | 14.77 Mn |
| Mar 31, 2022 | 15.47 Mn |
| Dec 31, 2021 | 13.30 Mn |
| Sep 30, 2021 | 18.30 Mn |